LifeSciVC

APRIL 2, 2024

For years, NBD1 was considered “undruggable”, but Sionna could be on the verge of a breakthrough with four programs in or entering the clinic this year leveraging years of experience and knowledge to crack the code on NBD1. We experienced strong enthusiasm for small molecule research in the investor community.

Science 67

Science Small Molecule International Clinical Development 67

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. 2 EvaluatePharma, World Preview 2020, Outlook to 2026. AstraZeneca PLC. _. This announcement contains inside information.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval. mg/dL reduction for placebo.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52